173 related articles for article (PubMed ID: 32659251)
101.
Bochicchio MT; Marconi G; Baldazzi C; Bandini L; Ruggieri F; Lucchesi A; Agostinelli C; Sabattini E; Orsatti A; Ferrari A; Capirossi G; Servili C; Ghelli Luserna di Rorà A; Martinelli G; Simonetti G; Rosti G
Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203288
[No Abstract] [Full Text] [Related]
102. Myeloid neoplasm with eosinophilia and
Cook JR; Rogers HJ; Chandra PK; Prescott JL; Mukherjee S
Leuk Lymphoma; 2020 Jan; 61(1):213-216. PubMed ID: 31482743
[No Abstract] [Full Text] [Related]
103. ETV6 mutations in early immature human T cell leukemias.
Van Vlierberghe P; Ambesi-Impiombato A; Perez-Garcia A; Haydu JE; Rigo I; Hadler M; Tosello V; Della Gatta G; Paietta E; Racevskis J; Wiernik PH; Luger SM; Rowe JM; Rue M; Ferrando AA
J Exp Med; 2011 Dec; 208(13):2571-9. PubMed ID: 22162831
[TBL] [Abstract][Full Text] [Related]
104. A novel ETV6-NTRK3 gene fusion in primary renal fibrosarcoma.
Jiang H
Eur Rev Med Pharmacol Sci; 2022 Jul; 26(13):4705-4708. PubMed ID: 35856362
[TBL] [Abstract][Full Text] [Related]
105. ETV6-related thrombocytopenia and leukemia predisposition.
Di Paola J; Porter CC
Blood; 2019 Aug; 134(8):663-667. PubMed ID: 31248877
[TBL] [Abstract][Full Text] [Related]
106. ETV6-NTRK3 fusion oncogene initiates breast cancer from committed mammary progenitors via activation of AP1 complex.
Li Z; Tognon CE; Godinho FJ; Yasaitis L; Hock H; Herschkowitz JI; Lannon CL; Cho E; Kim SJ; Bronson RT; Perou CM; Sorensen PH; Orkin SH
Cancer Cell; 2007 Dec; 12(6):542-58. PubMed ID: 18068631
[TBL] [Abstract][Full Text] [Related]
107. A Poorly Differentiated Non-keratinizing Sinonasal Squamous Cell Carcinoma with a Novel ETV6-TNFRSF8 Fusion Gene.
Bubola J; MacMillan CM; Weinreb I; Witterick I; Swanson D; Zhang L; Antonescu CR; Dickson BC
Head Neck Pathol; 2021 Dec; 15(4):1284-1288. PubMed ID: 33394379
[TBL] [Abstract][Full Text] [Related]
108. ETV6 germline mutations cause HDAC3/NCOR2 mislocalization and upregulation of interferon response genes.
Fisher MH; Kirkpatrick GD; Stevens B; Jones C; Callaghan M; Rajpurkar M; Fulbright J; Cooper MA; Rowley J; Porter CC; Gutierrez-Hartmann A; Jones K; Jordan C; Pietras EM; Di Paola J
JCI Insight; 2020 Sep; 5(18):. PubMed ID: 32841218
[TBL] [Abstract][Full Text] [Related]
109. Driver Fusions and Their Implications in the Development and Treatment of Human Cancers.
Gao Q; Liang WW; Foltz SM; Mutharasu G; Jayasinghe RG; Cao S; Liao WW; Reynolds SM; Wyczalkowski MA; Yao L; Yu L; Sun SQ; ; ; Chen K; Lazar AJ; Fields RC; Wendl MC; Van Tine BA; Vij R; Chen F; Nykter M; Shmulevich I; Ding L
Cell Rep; 2018 Apr; 23(1):227-238.e3. PubMed ID: 29617662
[TBL] [Abstract][Full Text] [Related]
110. Germline ETV6 mutations in familial thrombocytopenia and hematologic malignancy.
Zhang MY; Churpek JE; Keel SB; Walsh T; Lee MK; Loeb KR; Gulsuner S; Pritchard CC; Sanchez-Bonilla M; Delrow JJ; Basom RS; Forouhar M; Gyurkocza B; Schwartz BS; Neistadt B; Marquez R; Mariani CJ; Coats SA; Hofmann I; Lindsley RC; Williams DA; Abkowitz JL; Horwitz MS; King MC; Godley LA; Shimamura A
Nat Genet; 2015 Feb; 47(2):180-5. PubMed ID: 25581430
[TBL] [Abstract][Full Text] [Related]
111. Translocations and Gene Fusions in Sinonasal Malignancies.
Larkin R; Hermsen MA; London NR
Curr Oncol Rep; 2023 Apr; 25(4):269-278. PubMed ID: 36753024
[TBL] [Abstract][Full Text] [Related]
112. ETV6-related thrombocytopenia: dominant negative effect of mutations as common pathogenic mechanism.
Faleschini M; Ammeti D; Papa N; Alfano C; Bottega R; Fontana G; Capaci V; Zanchetta ME; Pozzani F; Montanari F; Petroni V; Giordano P; Noris P; Giona F; Savoia A
Haematologica; 2022 Sep; 107(9):2249-2254. PubMed ID: 35586967
[No Abstract] [Full Text] [Related]
113. Targeting chromatin complexes in fusion protein-driven malignancies.
Brien GL; Stegmaier K; Armstrong SA
Nat Rev Cancer; 2019 May; 19(5):255-269. PubMed ID: 30962549
[TBL] [Abstract][Full Text] [Related]
114. Mutation-associated fusion cancer genes in solid tumors.
Kaye FJ
Mol Cancer Ther; 2009 Jun; 8(6):1399-408. PubMed ID: 19509239
[TBL] [Abstract][Full Text] [Related]
115. Small Molecule Inhibitors as Therapeutic Agents Targeting Oncogenic Fusion Proteins: Current Status and Clinical.
Kong Y; Jiang C; Wei G; Sun K; Wang R; Qiu T
Molecules; 2023 Jun; 28(12):. PubMed ID: 37375228
[TBL] [Abstract][Full Text] [Related]
116. Tel1/ETV6 specifies blood stem cells through the agency of VEGF signaling.
Ciau-Uitz A; Pinheiro P; Gupta R; Enver T; Patient R
Dev Cell; 2010 Apr; 18(4):569-78. PubMed ID: 20412772
[TBL] [Abstract][Full Text] [Related]
117. A Multipronged Screening Approach Targeting Inhibition of ETV6 PNT Domain Polymerization.
Gerak CAN; Zhang SM; Balgi AD; Sadowski IJ; Sessions RB; McIntosh LP; Roberge M
SLAS Discov; 2021 Jun; 26(5):698-711. PubMed ID: 33345679
[TBL] [Abstract][Full Text] [Related]
118. Commonality but diversity in cancer gene fusions.
Rabbitts TH
Cell; 2009 May; 137(3):391-5. PubMed ID: 19410533
[TBL] [Abstract][Full Text] [Related]
119. Fusion genes in solid tumors: an emerging target for cancer diagnosis and treatment.
Parker BC; Zhang W
Chin J Cancer; 2013 Nov; 32(11):594-603. PubMed ID: 24206917
[TBL] [Abstract][Full Text] [Related]
120. Identification of recurrent fusion genes across multiple cancer types.
Yu YP; Liu P; Nelson J; Hamilton RL; Bhargava R; Michalopoulos G; Chen Q; Zhang J; Ma D; Pennathur A; Luketich J; Nalesnik M; Tseng G; Luo JH
Sci Rep; 2019 Jan; 9(1):1074. PubMed ID: 30705370
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
